Capstone Investment Advisors
IOVA icon

Capstone Investment Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Capstone Investment Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,939
Closed -$136K – 2058
2024
Q2 		$136K Buy
+16,939
New +$182K ﹤0.01% 1846
2024
Q1 		– Sell
-20,785
Closed -$169K – 2428
2023
Q4 		$169K Sell
20,785
-7,722
-27% -$40.4K ﹤0.01% 1828
2023
Q3 		$130K Buy
28,507
+13,139
+85% +$85.8K ﹤0.01% 1910
2023
Q2 		$108K Buy
+15,368
New +$110K ﹤0.01% 1686

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capstone Investment Advisors's IOVA Position: Q3 2024 in Review

Capstone Investment Advisors sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 16,939 shares — an estimated $136K sold.

Capstone Investment Advisors first reported a position in IOVA in Q2 2023 and held it in 4 quarters. The position peaked at $169K in Q4 2023. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Capstone Investment Advisors reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 16,939 Iovance Biotherapeutics shares in Q3 2024, an estimated $136K.
  • Capstone Investment Advisors first reported a position in Iovance Biotherapeutics in Q2 2023 and held it in 4 quarters.
  • Capstone Investment Advisors's Iovance Biotherapeutics position peaked at $169K in Q4 2023.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Capstone Investment Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.